Group 1 - Danaher announced the acquisition of Masimo for $9.9 billion, expanding its presence in the patient monitoring equipment sector, with a valuation of $180 per share, representing a 38.3% premium over Masimo's previous closing price [1] - Danaher, valued at $150 billion, is primarily focused on drug development and testing tools, marking this acquisition as a new venture outside its core business [1] - Masimo specializes in non-invasive monitoring devices for hospitals, including pulse oximeters and brain activity monitors, and has been in the spotlight due to patent disputes with Apple [1] Group 2 - The acquisition will enhance Danaher's diagnostic product matrix by integrating Masimo's non-invasive monitoring devices with its existing invasive Radiometer blood analysis product line [2] - Danaher expects an increase in adjusted diluted earnings per share by $0.15 to $0.20 in the first full fiscal year post-acquisition, and approximately $0.70 by the fifth full fiscal year, with the deal anticipated to close in the second half of 2026 [2] - The transaction is expected to generate over $125 million in annual cost synergies [2]